A funded push into randomised testing

Faron Pharmaceuticals Ltd (LSE:FARN), the Finnish immuno-oncology developer, enters the final quarter of 2026 with a strengthened balance sheet and plans to start a randomised Phase 2b trial of its lead antibody, bexmarilimab, in higher-risk myelodysplastic syndrome (MDS). The company's half-year results, published on 26 August 2026, showed cash of €32.0 million following a rights issue earlier in the year. More recently, on 30 September, Faron announced that a convertible bond amortisation payment had been deferred by mutual agreement with its bondholder, HCM.

What the company does

Headquartered in Turku, Faron is a clinical-stage biopharmaceutical company listed on AIM and on Nasdaq First North Finland. Its approach targets Clever-1, a receptor on immune cells called macrophages, with the aim of reprogramming these myeloid cells to switch on the body's anti-tumour immunity. Bexmarilimab, a wholly owned anti-Clever-1 antibody, is being studied in blood cancers, including MDS and acute myeloid leukaemia, and in solid tumours.

Latest developments

Faron said its planned BEXERA study will test bexmarilimab with azacitidine in previously untreated higher-risk MDS, enrolling 90 participants at up to 35 sites in the US, Europe and UK, with a start expected in the second half of 2026. Clinical services organisation Parexel was appointed in April. At the European Hematology Association congress in June, the company reported a median complete remission duration of 16.1 months in treatment-naive patients in its earlier BEXMAB Phase 1/2 study. A first overall survival data cut, released on 27 July, was described by Faron as encouraging, although only one subgroup had reached a median survival figure at that stage.

Several investigator-initiated trials are also under way, covering soft-tissue sarcoma, melanoma and lung cancer, and acute myeloid leukaemia after transplant, while a dedicated Phase 2 AML trial is planned. In September the company issued warrants, and board and management changes earlier in the year included the appointment of a new chief technology officer.

Financial picture

For the six months to 30 June 2026, R&D spending rose to €7.6 million while administrative costs fell to €3.5 million, giving an operating loss of €11.1 million compared with €11.8 million a year earlier. The rights issue raised gross proceeds of about €40.1 million, and shares outstanding rose to roughly 203 million. Borrowings, largely convertible bonds, remained significant. As a development-stage company, Faron has no product revenue and pays no dividend, and it does not provide a short-term outlook.

Sector and index context

Faron is one of a number of overseas-domiciled companies tracked by the FTSE AIM All Share Index, and it sits in the healthcare segment, where valuations are typically driven by clinical data and funding news rather than earnings. Small-cap biotech sentiment has been mixed, and companies with registrational ambitions often seek partners to share late-stage costs. Faron's chief executive has said partnering discussions are ongoing.

Key risks

Clinical trials may fail to confirm earlier results, and the Phase 2b study has yet to enrol its first patient. Bond repayment obligations, including the deferral agreed in September, add financing complexity, and further share issuance could dilute shareholders. Regulatory requirements for any eventual filing also remain to be settled.

What to watch next

Key milestones include the first patient dosed in BEXERA, updated survival data from the BEXMAB study, readouts from investigator-led trials and progress in partnering discussions. Investors will also follow how the company manages its convertible bond schedule and whether its cash runway is extended.